Merck, Schering Offer $42M To Settle Vytorin Suits

Law360, New York (August 5, 2009, 5:16 PM EDT) -- Pharmaceutical giants Merck & Co. and Schering-Plough Corp. have said they will pay $41.5 million to settle a host of civil lawsuits over joint marketing and studies of the cholesterol drug Vytorin.

The companies made the announcement Wednesday, saying the deal would settle all class actions — including claims for attorneys' fees, costs and nongovernmental liens — that seek damages related to purchases of the drugs Vytorin and Zetia.

"These agreements will allow the companies to avoid continuing defense costs and remain focused on discovering, developing...
To view the full article, register now.